CAMBRIDGE, Mass., May 07, 2010 (BUSINESS WIRE) -- Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will issue
its first quarter 2010 investor update after the U.S. financial markets
close on Tuesday, May 11, 2010. In connection with this announcement,
Ironwood will host a conference call and webcast at 4:30 p.m. Eastern
Time on Wednesday, May 12, 2010. Individuals interested in participating
in the call should dial (888) 686-9681 (U.S. and Canada) or (913)
312-1451 (international) using conference ID number 1030465. To access
the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required. The call will be
available for replay via telephone starting May 12, 2010 at 7:30 p.m.
Eastern Time, running through 11:59 p.m. Eastern Time on May 26, 2010.
To listen to the replay, dial (888) 203-1112 (U.S. and Canada) or (719)
457-0820 (international) using conference ID number 1030465. An archived
version of the event will be available on Ironwood's website for 14 days
beginning approximately one hour after the call.
The company also announced that Peter Hecht, Ironwood's chief executive
officer, will present at the Bank of America Merrill Lynch 2010 Health
Care Conference on Thursday, May 13, 2010 at 11:20 a.m. Eastern Time. A
live webcast of Ironwood's presentation will be accessible through the
Investors section of the company's website at www.ironwoodpharma.com.
To access the webcast, please log on to the Ironwood website at least 15
minutes prior to the start of the presentation to ensure adequate time
for any software downloads that may be required. A replay of the webcast
will be available on Ironwood's website for 14 days.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial
pharmaceutical company dedicated to the art and science of great
drugmaking. Linaclotide, Ironwood's GC-C agonist, is being evaluated in
a confirmatory Phase 3 program for the treatment of irritable bowel
syndrome with constipation (IBS-C) and chronic constipation. Ironwood
also has a growing pipeline of additional drug candidates in earlier
stages of development. Ironwood is located in Cambridge, Mass.
SOURCE: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Susan Brady, 617-621-8304
Corporate Communications
sbrady@ironwoodpharma.com
Copyright Business Wire 2010